GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medixall Group MDXL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$309,422

FY2015FY2024

Net income

−$4.6m

FY2015FY2024

Free cash flow

−$1.2m

FY2015FY2024

Shareholders' equity

−$6.5m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$309,422$59,268$59,268$14,995—$2,685$1,858$22,232——
Research and development—$38,822————————
Operating income−$3.9m−$6.5m−$6.3m−$6.5m−$5.9m−$3.4m−$2,897−$1.6m−$657,160−$348,621
Net income−$4.6m−$6.8m−$6.8m−$6.0m−$5.9m−$3.4m−$3.0m−$1.6m−$657,160−$348,621
Diluted earnings per share-0.03-0.05-0.06-0.05-0.06-0.04-0.05-0.03-0.25-0.14

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$201,103$862,013$862,013$1.1m$1.6m$937,980$728,720$367,746$114,971$25,000
Cash and short-term investments$10,721$3,416—$63,418$645,762$446,219$201,509$191,440$114,971−$24,975
Total liabilities$6.7m$4.5m$4.5m$1.5m$1.3m$540,220$185,759$592,281$1.0m$1.0m
Debt$3.8m$2.8m—$315,631$212,919$117,639————
Shareholders' equity−$6.5m−$3.7m−$3.7m−$340,122$381,904$397,760$542,961−$224,535−$905,530−$1.0m
Shares outstanding130m130m117m111m99m81m59m63m3m3m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$1.2m−$3.6m−$3.6m−$4.7m−$3.5m−$2.3m−$2.2m−$2.1m−$666,154$24,622
Capital spending—−$1,379−$1,379−$12,840−$91,574−$15,745−$281,545−$179,306−$11,504−$11,504
Free cash flow−$1.2m−$3.6m−$3.6m−$4.7m−$3.6m−$2.4m−$2.5m−$2.2m−$677,658$13,118

Latest quarters

By quarter end

Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023
Revenue$38,858$52,839$94,497$38,858$52,839$65,535$94,497$65,535
Operating income−$300,528−$380,027−$979,057−$300,528−$380,027−$871,065−$979,057−$871,065
Net income$263,813−$485,862−$1.5m$263,813−$485,862−$908,067−$1.5m−$908,067
Diluted earnings per share0.00-0.00-0.010.00-0.00-0.01-0.01-0.01
Total assets$219,980$229,333$201,103$219,980$229,333$455,501$201,103$455,501
Cash and short-term investments$31,916$32,621$10,721——$9,667——
Debt$396,514$4.7m$3.8m$39,655$37,148$3.7m——
Shareholders' equity−$3.6m−$7.5m−$6.5m−$3.6m−$7.5m−$5.2m−$6.5m−$5.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue174.3%158.4%—
Operating income-15.7%2.7%19.1%
Net income-8.9%5.9%20.9%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-2836.1%-5262.3%——
Net margin-3090.4%-5476.7%——

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2019FY2018FY2017
Price to earnings-0.1—-0.1-0.0———
Price to sales0.90.39.82.94.43.10.3

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-97%1425%-97%813%90%42%90%0%60%-36%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 15-to-1 reverse split · 22 Nov 2016
  • 200-to-1 reverse split · 9 Aug 2013
  • 250-to-1 reverse split · 27 Sept 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.